TherapeuticsMD, Inc. (TXMD)
| Market Cap | 465.93M |
| Revenue (ttm) | 64.87M |
| Net Income (ttm) | -183.52M |
| Shares Out | 275.65M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $1.14 |
| Previous Close | $1.19 |
| Change ($) | -0.05 |
| Change (%) | -4.22% |
| Day's Open | 1.17 |
| Day's Range | 1.12 - 1.19 |
| Day's Volume | 3,647,191 |
| 52-Week Range | 0.90 - 2.75 |
TherapeuticsMD (TXMD) stock is up on Friday after announcing approval for one of its hormone treatments in two parts of Europe. The post TXMD Stock: The News Giving TherapeuticsMD Shares a Shot in the A...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, and Theramex, a dedicated women's health company, announced that BIJUVE® has re...
Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...
LONDON--(BUSINESS WIRE)--Theramex, a global company specialised in women's health, announced today the Decentralised Procedure approval in several EU countries and the UK of BIJUVA® (1 mg estradiol / 10...
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of TherapeuticsMD (NASDAQ:TXMD) rose 9.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.05% over the past year to ($0.15), which missed...
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD net product revenue in 2020 increased 84% over 2019; conference call at 8:30am ET today to discuss financial and business results for 2020.
BOCA RATON, Fla.--(BUSINESS WIRE)--March Conferences
TherapeuticsMD (TXMD) closed the most recent trading day at $1.63, moving +1.24% from the previous trading session.
BOCA RATON, Fla.--(BUSINESS WIRE)--4Q date announcement press release
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 59,459,460 shares of its common stock for net proceeds of approxi...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross p...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purc...
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...
Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by m...
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at H.C. Wainwright BioConnect Conference and J.P. Morgan Virtual HealthCare Conference in January 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD closes offering; sold 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross p...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purc...
TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases Q3 business and financial results; holds conference call at 8:30 am ET today
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to hold conference call to discuss Q3 financial and business results on Monday, November 9 at 8:30 am ET
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Give TXMD stock a try if you're ready to expand your portfolio's horizons with a stake in innovative women's health care products. The post Delve into an Underappreciated Health Care Niche with Therapeu...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choices about t...
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
BOCA RATON, Fla.--(BUSINESS WIRE)--3Q Update PR
MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval...
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to participate in two virtual investor conferences in September
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD increases patent protection on ANNOVERA
TherapeuticsMD has been a blemish on my speculative biotech/pharma portfolio for over a year. I went against my rules for trading a premium-priced bio and paid for it.
MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval o...
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q2 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD discusses business and financial results for Q2 2020 on earnings conference call today at 8:30 a.m.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc.
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOCA RATON, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--TXMD expands access to Annovera through arrangement with Nurx, the largest online practice for women's health
Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only going to get...
Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q1 2020 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
A newly issued patent could provide market exclusivity for its long-term contraceptive device.
About TXMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Robert Finizio | Employees 400 |
| Stock Exchange NASDAQ | Ticker Symbol TXMD |
Financial Performance
In 2020, TherapeuticsMD's revenue was $64.87 million, an increase of 30.67% compared to the previous year's $49.65 million. Losses were -$183.52 million, 4.19% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for TherapeuticsMD stock is "Strong Buy." The 12-month stock price forecast is 6.17, which is an increase of 443.61% from the latest price.